KC
DMIIU

Kepos Capital’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

Kepos Capital’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-210,000
Closed -$2.11M – 192
2026
Q1 		$2.11M Buy
+210,000
New +$2.11M 3.44% 3

Other funds holding DMIIU

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $142M AUM
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Kepos Capital's DMIIU Position: Q2 2026 in Review

Kepos Capital sold out of Drugs Made In America Acquisition II Corp Unit (DMIIU) in Q2 2026, closing a stake of 210,000 shares — an estimated $2.11M sold.

Kepos Capital first reported a position in DMIIU in Q1 2026 and held it in 1 quarter. The position peaked at $2.11M in Q1 2026. 11 funds tracked by Wall St. Rank hold DMIIU as of Q2 2026.

  • Kepos Capital reported no remaining Drugs Made In America Acquisition II Corp Unit position as of Q2 2026 after selling out during the quarter.
  • Kepos Capital sold 210,000 Drugs Made In America Acquisition II Corp Unit shares in Q2 2026, an estimated $2.11M.
  • Kepos Capital first reported a position in Drugs Made In America Acquisition II Corp Unit in Q1 2026 and held it in 1 quarter.
  • Kepos Capital's Drugs Made In America Acquisition II Corp Unit position peaked at $2.11M in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q2 2026.

Based on Kepos Capital's 13F filing for Q2 2026, filed 13 Aug 2026.